E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Bacterial Infections and Mycoses [C01] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 17.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10004049 |
E.1.2 | Term | Bacterial meningitis |
E.1.2 | System Organ Class | 100000004862 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the safety of bivalent rLP2086 vaccine compared to a control
(hepatitis A virus [HAV] vaccine/saline), as assessed by serious adverse
events (SAEs) and medically attended adverse events. |
|
E.2.2 | Secondary objectives of the trial |
To evaluate the safety profile of bivalent rLP2086 vaccine compared to a
control (HAV/saline), as measured by AEs, SAEs, newly diagnosed
chronic medical conditions, medically attended adverse events and
immediate AEs. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the study:
1. Evidence of a personally signed and dated informed consent document indicating that
the subject (and/or a parent/ legally authorized representative) has been informed of all pertinent aspects of the study.
2. parent/legally authorized representative and/or subject who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
3. Male or female subjects aged ≥10 and <26 years at time of enrollment.
4. Available for the entire study period and can be reached by telephone.
5. Healthy subject as determined by medical history, physical examination, and judgment of the investigator.
6. Male and female subjects of childbearing potential must agree to use a
highly effective method of contraception throughout the study (through
the follow-up telephone contact at month 12). A subject is of
childbearing potential if, in the opinion of the investigator, he/she is
biologically capable of having children and is sexually active. Refer to
Protocol Section 4.4 for further information.
7. Negative urine pregnancy test for all female subjects. |
|
E.4 | Principal exclusion criteria |
Subjects presenting with any of the following will not be included in the study:
1. Subjects who are investigational site staff members or subjects who are Pfizer employees directly involved in the conduct of the trial.
2. Subject is a direct descendant (e.g. child, grandchild or other family member) of study
site personnel.
3. Previous vaccination with any meningococcal serogroup B vaccine.
4. Subjects receiving any allergen immunotherapy with a non-licensed
product or receiving allergen immunotherapy with a licensed product
and not on stable maintenance doses.
5. Subjects who are scheduled to receive one or more doses of a human
papillomavirus (HPV) vaccination as part of a 3-dose series during the
period between Visit 1 and 28 days after the second study vaccination
(Visit 3).
6. A previous anaphylactic reaction to any vaccine or vaccine-related component.
7. Bleeding diathesis or condition associated with prolonged bleeding time that would
contraindicate intramuscular injection.
8. A known or suspected defect of the immune system that would prevent an immune response to the vaccine, such as subjects with congenital or acquired defects in B cell function, those receiving chronic systemic (oral, intravenous or intramuscular) corticosteroid therapy or those receiving immunosuppressive therapy. Subjects in the United States with terminal complement deficiency are excluded from participation in this study. Please refer to the SRM for additional details.
9. History of microbiologically proven disease caused by Neisseria meningitidis or Neisseria gonorrhoea.
10. Significant neurological disorder or history of seizure (excluding simple febrile seizure).
11. Receipt of any blood products, including immunoglobulin within 6 months before the
first study vaccination.
12. Current participation in another investigational study. Participation in purely
observational studies is acceptable.
13. Received any investigational vaccines, drugs or devices within 28 days before administration of
the first study vaccination.
14. Any neuroinflammatory and autoimmune condition, including but not limited to transverse myelitis, uveitis, optic neuritis, and multiple sclerosis.
15. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
16. Subject is pregnant or breastfeeding.
17. Subjects who are investigational site staff members or relatives of
those site staff members, or subjects who are Pfizer employees directly
involved in the conduct of the trial or relatives of those Pfizer
employees. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
- Percentage of subjects with at least one SAE occurring during the time
period from the first study vaccination (Visit 1) through 6 months after
last study vaccination (Visit 9).
- Percentage of subjects with at least one medically attended adverse |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
14 months after last subject last visit. |
|
E.5.2 | Secondary end point(s) |
Percentage of subjects with at least 1 SAE during the following time
periods:
30 days after each vaccination
30 days after any vaccination
During the vaccination phase [from the first study vaccination (visit 1)
through 1 month after the last study vaccination (visit 8)]
During the follow-up phase [from one month after the last study
vaccination (visit 8) through 6 months after the third study vaccination
(visit 9)]
Percentage of subjects with at least one medically attended adverse
event occurring during the following time periods:
30 days after any vaccination
During the vaccination phase [from the first study vaccination (visit 1)
through 1 month after the last study vaccination (visit 8)]
During the follow-up phase [from 1 month after the last study
vaccination (visit 8) through 6 months after the third study vaccination
(visit 9)]
Throughout the study period [from the first study vaccination (visit 1)
through 6 months after the third study vaccination (visit 9)]
Percentage of subjects with at least one newly diagnosed chronic
medical condition occurring during the following time periods:
30 days after each vaccination
30 days after any vaccination
During the vaccination phase [from the first study vaccination (visit 1)
through 1 month after the last study vaccination (visit 8)]
During the follow-up phase [from one month after the last study
vaccination (visit 8) through 6 months after the third study vaccination
(visit 9)]
Throughout the study period [from the first study vaccination (visit 1)
through 6 months after the third study vaccination (visit 9)]
Percentage of subjects with at least one adverse event occurring during
the following time periods:
30 days after each vaccination
30 days after any vaccination
During the vaccination phase [from the first study vaccination (visit 1)
through 1 month after the last study vaccination (visit 8)]
Percentage of subjects reporting at least 1 immediate AE after each
vaccination
Subject's days missing school or work due to AEs during the vaccination
phase (Visit 1 through Visit 8). |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
14 months after last subject last visit. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | Yes |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Information not present in EudraCT |
E.8.4 | The trial involves multiple sites in the Member State concerned | Information not present in EudraCT |
E.8.4.1 | Number of sites anticipated in Member State concerned | 6 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 33 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Australia |
Chile |
Czech Republic |
Denmark |
Estonia |
Finland |
Germany |
Lithuania |
Poland |
Spain |
Sweden |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 20 |
E.8.9.2 | In all countries concerned by the trial days | 0 |